Cytosorbents Corporation (NASDAQ:CTSO) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET
Company Participants
Terri Anne Powers - Vice President, Investor Relations & Corporate Communications
Phillip Chan - Chief Executive Officer
Vincent Capponi - President & Chief Operating Officer
Kathleen Bloch - Chief Financial Officer
Christian Steiner - Executive Vice President, Sales & Marketing and Managing Director of Cytosorbents Europe
Christopher Cramer - Vice President, Business Development
Efthymios Deliargyris - Chief Medical Officer
Conference Call Participants
Frank Pinal - Jefferies
Justin Walsh - B. Riley Securities
Zach Weiner - Jefferies
Priya Sachdeva - SVB
Operator
Good afternoon and welcome to the Cytosorbents Corp.'s First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for questions. Please be advised that the call will be recorded at the company's request.
At this time I would like to turn the call over to our moderator Terri Anne Powers, Vice President of Investor Relations and Corporate Communications. Please go ahead Ms. Powers.
Terri Anne Powers
Thank you, Stacy. Good afternoon. Welcome to the Cytosorbents' first quarter 2022 financial and operating results conference call. Joining me today from the company are Dr. Phillip Chan, our Chief Executive Officer; Vincent Capponi, President and Chief Operating Officer; Kathleen Bloch, Chief Financial Officer; Dr. Efthymios Deliargyris, our Chief Medical Officer; Dr. Christian Steiner, Executive Vice President of Sales and Marketing and Managing Director of Cytosorbents Europe; and Christopher Cramer, our Vice President of Business Development.
Before I turn the call over to Dr. Chan, I'd like to remind listeners that during the call management's prepared remarks may contain forward-looking statements which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore the company claims protection under Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Actual results may differ from results discussed today and therefore we refer to you -- we refer you to a more detailed discussion of these risks and uncertainties in the company's filings with the SEC. Any projections as to the company's future performance represented by management include estimates today as of May 3rd, 2022 and we assume no obligation to update these projections in the future.
During today's call, we will have an overview presentation covering the operating and financial highlights for the first quarter of 2022 by management. Following that presentation, we will open the line to your questions with the management team.